SureGene

This article has been updated to include information about a competing product in the market.

The pharmacy benefits manager will study whether its members are more willing to take -- and stick with -- antidepressant and antipsychotic drugs prescribed to them based on a genetic test that suggests they are most likely to benefit from such treatment.

The company has received a $224,500 Therapeutic Discovery Project Tax Credit and a $365,579 SBIR Phase II matching grant from the Commonwealth of Kentucky to continue the development of a predictive test to guide treatment of antipsychotic drugs.

The alliance aims to validate whether polymorphisms identified by SureGene in the SULT4A1 gene can be used to stratify best responders to the four most widely prescribed atypical antipsychotics.

The two firms will study whether genetic variations can help predict response to widely prescribed antipsychotic drugs.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.